Drugs / Priorix™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00352898 | Apr → Nov 2006 | measles, mumps infectious disease, rubella, varicella zoster infection | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-06 | GlaxoSmithKline | Regulatory GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older gsk.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-06 | GlaxoSmithKline | GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Priorix | “Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™)” NCT00352898 ↗ |
| Known as | MMR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00352898 ↗ |
| Modality | Vaccine | “Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™)” NCT00352898 ↗ |